A small-scale retrospective analysis of patients treated with HD IL-2 following disease progression after PD-1 or PD-L1 inhibitor treatment showed that prior checkpoint inhibitor therapy may not be detrimental to subsequent treatment with HD IL-2 in patients with RCC. Here, PDCD1 is linked to renal cell carcinoma.